UTHR United Therapeutics (UTHR) Q2 FY26 earnings call
United Therapeutics reported a quarter marked by significant pipeline advancements, including key regulatory submissions for ralinepag in PAH and nebulized Tyvaso in IPF, alongside progress in its organ pipeline. Despite these scientific successes, commercial performance for existing products, particularly nebulized Tyvaso, faced competitive pressures, resulting in Q2 revenue below expectations. The company is focused on accelerating performance in the second half of 2026 through an expanded sales force, while emphasizing the multi-billion dollar potential of its upcoming launches to drive fut
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.